By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Personalized medicine software firm Proventys has raised nearly $3.3 million in an offering it hopes will bring in a total of $5.1 million, the firm said in a document filed with the US Securities and Exchange Commission.

The company did not say how the funds would be used.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.